Search results for "Cystadenocarcinoma"

showing 6 items of 16 documents

High-dose folinic acid and 5-fluorouracil plus cisplatin on a weekly schedule in the treatment of advanced cancer of the head and neck

1992

A group of 60 patients with advanced head/neck cancer were treated with high-dose folinic acid (500 mg/m-2/week-1) plus 5-fluorouracil (400 mg/m-2/week-1 on day 1, and cisplatin (20 mg/m-2/week-1) 24 h after folinic acid infusion was completed. Out of 55 evaluable patients, 10 patients (18%) experienced a complete response with a mean duration of 11.4+ months, 25 patients had a partial response (45%) of 6.7+ months, 6 patients (11%) showed a stabilization of 4.8+ months, and 14 (25%) progressed. The overall response rate was 63.6% (95% confidence limits 56.5%-69.5%). Patients pretreated with radiotherapy had a 67% overall response rate, while those pretreated with chemotherapy showed a 54% …

MaleCancer Researchmedicine.medical_specialtyNauseamedicine.medical_treatmentCystadenocarcinomaLeucovorinAdenocarcinomaGastroenterologyDrug Administration ScheduleFolinic acidInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansNeoplasm MetastasisChemotherapyLeukopeniabusiness.industryCarcinomaCancerGeneral MedicineMiddle Agedmedicine.diseaseRadiation therapyOncologyHead and Neck NeoplasmsFluorouracilAnesthesiaCarcinoma Squamous CellVomitingFemaleFluorouracilCisplatinmedicine.symptombusinessmedicine.drugJournal of Cancer Research and Clinical Oncology
researchProduct

Excision repair cross-complementation group 1 protein overexpression as a predictor of poor survival for high-grade serous ovarian adenocarcinoma.

2010

Abstract Objective The excision repair cross-complementation group 1 (ERCC1) expression is a predictor of survival after surgical treatment for several malignancies. Its overexpression has been reported as a marker of platinum resistance in lung cancer. However, the relevance of ERCC1 expression in ovarian cancer (OC) is the subject of controversy, both as a predictive parameter for platinum resistance and because of its association with poor prognosis. Therefore, we performed a retrospective study investigating ERCC1 expression and its correlation with patients' survival in OC. Methods We analyzed the ERCC1 protein expression using four different ERCC1 antibodies (clone 8F1) with different…

OncologyAdultmedicine.medical_specialtyNeoplasm Residualmedicine.medical_treatmentERCC1 Protein ExpressionPredictive Value of TestsInternal medicineOvarian carcinomamedicineHumansLung cancerSurvival rateAgedNeoplasm StagingRetrospective StudiesAged 80 and overOvarian NeoplasmsChemotherapybusiness.industryAge FactorsObstetrics and GynecologyMiddle Agedmedicine.diseaseEndonucleasesImmunohistochemistryCystadenocarcinoma SerousDNA-Binding ProteinsSerous fluidOncologyFemaleERCC1businessOvarian cancerGynecologic oncology
researchProduct

Mesenteric Lymph Node Involvement in Advanced Ovarian Cancer Patients Undergoing Rectosigmoid Resection: Prognostic Role and Clinical Considerations

2014

Background: The aim of this retrospective study was to investigate the incidence of mesenteric lymph node (MLN) involvement, and its prognostic role in advanced ovarian cancer (OC). Methods: OC patients undergoing rectosigmoid resection during primary debulking surgery or interval debulking surgery were recorded. Progression-free survival (PFS) and overall survival were calculated from the date of diagnosis to the date of relapse/progression, death of disease, or the date of last follow-up. Results: MLNs were detected in 102/148 cases (68.9 %); the rate of MLN involvement was 47.0 %. The percentage of metastatic MLNs was higher in cases with >5 MLNs removed compared with cases with ≤5 MLNs …

OncologySettore MED/18 - CHIRURGIA GENERALEGastroenterologyClear CellSurgical oncology80 and overMucinousMesenteryCystadenocarcinomaLymph nodeAged 80 and overOvarian NeoplasmsMedicine (all)Middle AgedDebulkingPrognosisAdenocarcinoma MucinousOVARIAN CANCERSurvival Ratemedicine.anatomical_structureOncologyLymphatic MetastasisAdenocarcinomaFemaleAdultmedicine.medical_specialtyCystadenocarcinomaAdenocarcinomaAdenocarcinoma Clear Cell; Adenocarcinoma Mucinous; Adult; Aged; Aged 80 and over; Cystadenocarcinoma Serous; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Mesentery; Middle Aged; Neoplasm Grading; Ovarian Neoplasms; Prognosis; Rectum; Retrospective Studies; Sigmoid Neoplasms; Survival Rate; Surgery; OncologyInternal medicinemedicineHumansSurvival rateAgedRetrospective Studiesbusiness.industryRectumSerousRetrospective cohort studymedicine.diseaseCystadenocarcinoma SerousEndometrial NeoplasmsSigmoid NeoplasmsSettore MED/40 - GINECOLOGIA E OSTETRICIALymph Node ExcisionSurgeryLymph NodesNeoplasm GradingOvarian cancerbusinessAdenocarcinoma Clear CellFollow-Up Studies
researchProduct

Characterization of a Human Carcinosarcoma Cell Line of the Ovary Established after in Vivo Change of Histologic Differentiation

2001

Abstract Objectives. Cell lines are valuable in vitro models for clinical and basic research. Most ovarian cancer cell lines described are serous cystadenocarcinomas or poorly differentiated adenocarcinomas. The establishment of ovarian cancer cell lines with rare histologic differentiation is especially of interest. We describe the establishment of a carcinosarcoma cell line of the ovary after in vivo selection. Methods. The cell line OV-MZ-22 was established from a solid tumor mass in the upper abdomen. At the time of establishment, the patient underwent secondary debulking and was pretreated with six cycles of cis -platinum/epirubicin/cyclophosphamide. Features of the cell line studied i…

Pathologymedicine.medical_specialtySerous cystadenocarcinomaCellular differentiationMice NudeBiologyMicePapillary CystadenocarcinomaCarcinosarcomaIntermediate Filament ProteinsCarcinosarcomaTumor Cells CulturedmedicineAnimalsHumansCystadenocarcinomaOvarian NeoplasmsObstetrics and GynecologyCell DifferentiationDNA NeoplasmMiddle Agedmedicine.diseaseDebulkingActinsOncologyKaryotypingCystadenocarcinoma PapillaryKeratinsAdenocarcinomaFemaleNeoplasm Recurrence LocalOvarian cancerNeoplasm TransplantationGynecologic Oncology
researchProduct

Laparoscopic laterally extended pelvic resection for gynecological malignancies

2020

Lateral isolated gynecological cancer infiltrating the pelvic side wall has been considered non-operable with a poor oncological outcome.[1][1] The development of the laterally extended endopelvic resection and surgical progress for disease, overcoming the endopelvic fascia infiltrating muscles and

medicine.medical_specialtyCystadenocarcinomaLaparoscopesResection03 medical and health sciencesGynecologic Surgical Procedures0302 clinical medicinelaparoscopeGynecologic Surgical ProcedurelocalmedicineHumansAgedEndopelvic fasciaOvarian Neoplasms030219 obstetrics & reproductive medicineneoplasm recurrence localbusiness.industrySerousObstetrics and Gynecologyneoplasm recurrencemedicine.diseaseGynecological cancerCystadenocarcinoma SerousSurgerybody regionsCystadenocarcinoma SeroulaparoscopesSettore MED/40 - GINECOLOGIA E OSTETRICIAovarian cancerOncology030220 oncology & carcinogenesisFemaleLaparoscopybusinessOvarian cancer
researchProduct

Long term complications following pelvic and para-aortic lymphadenectomy for endometrial cancer, incidence and potential risk factors: a single insti…

2019

ObjectiveTo determine the incidence of long term lymphadenectomy complications in primary surgery for endometrial cancer and to elucidate risk factors for these complications.MethodsA retrospective chart review was carried out for all patients with endometrial cancer managed at Parma University Hospital Unit of Gynecology and Obstetrics between 2010 and 2016. Inclusion criteria were surgical procedure including hysterectomy and lymphadenectomy (pelvic or pelvic and aortic). We identified patients with postoperative lymphocele and lower extremity lymphedema. Logistic regression analysis was used to identify predictive factors for postoperative complications.ResultsOf the 249 patients tested,…

medicine.medical_treatmentLymphoceleLymphocele0302 clinical medicinePostoperative ComplicationsCarcinosarcomaRisk FactorsLymphedema030219 obstetrics & reproductive medicineIncidenceLymph NodeObstetrics and GynecologyMiddle AgedPrognosisCystadenocarcinoma SerouDissectionLymphedemaOncologyItaly030220 oncology & carcinogenesisendometrial cancerFemaleHumanmedicine.medical_specialtyPelviPrognosiSentinel lymph nodeFollow-Up StudiePelvis03 medical and health sciencesmedicineHumansEndometrial NeoplasmAgedHysterectomybusiness.industryRisk FactorEndometrial cancerOdds ratiomedicine.diseaseSurgeryCystadenocarcinoma SerousEndometrial NeoplasmslymphadenectomyLymph Node ExcisionLymphadenectomyLymph NodesbusinessAdenocarcinoma Clear CellFollow-Up StudiesInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society
researchProduct